# Amnis Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amnis

- Industry: Medical Devices & Equipment
- Headquarters: Seattle, US
- Website: www.amnis.com
- Total disclosed funding: $20M
- Latest round: Series D (Jul 26, 2009)
- Investors on record: 9

## About

Amnis Corporation operates as a specialist in flow cytometry technology, providing innovative solutions for biological research through advanced systems and reagents that enhance data collection and analysis.Founded in 1999 and headquartered in Seattle, US, Amnis Corporation develops advanced flow cytometry systems and reagents. The company was sold to EMD Millipore in August 2011, following a series of 7 deals. The founder's specific history is not disclosed.Amnis Corporation specializes in advanced flow cytometry systems, focusing on full spectrum flow cytometry technology. Their products include the Cytek Aurora™ series, Cytek Northern Lights™, and cFluor® reagents, designed to enhance the analysis of immune cells and biological samples. This technology allows researchers to conduct highly multiplexed assays with up to 40 colors, addressing the limitations of conventional flow cytometers. The offerings cater to researchers in immuno-oncology, infectious diseases, and drug discovery across North America, Europe, and Asia-Pacific, improving experimental efficiency and providing flexibility in panel design.Amnis Corporation generates revenue through the sale of flow cytometry instruments, reagents, and software solutions targeted at research institutions and laboratories. The business model includes direct sales and partnerships with distributors, focusing on one-time equipment purchases and ongoing sales of consumables and maintenance services. Flagship products like the Cytek Aurora™ and cFluor® reagents are key to their revenue, supplemented by subscriptions and training services that enhance customer satisfaction.Amnis Corporation's growth strategy involves designing new products and expanding into new markets. The latest funding from August 2011, amounting to USD 3.50 mn, will support these initiatives. The company aims to launch new advanced flow cytometry products and target expansion into Asia-Pacific markets by 2025, leveraging its technological advancements to address evolving research needs.

## Funding rounds

- Series D, Jul 26, 2009 — MedVenture Associates, OrbiMed Advisors, CVF Capital Partners
- Series C, Mar 28, 2006, $11M — MedVenture Associates, OrbiMed Advisors, TVM Capital Life Science, CVF Capital Partners, Emerging Technology Partners, Hillman Medical Ventures
- Series B, Dec 3, 2001, $8.8M — Integra Ventures, OrbiMed Advisors, TVM Capital Life Science, Emerging Technology Partners, WRF Capital, Hillman Medical Ventures, Stratos Management Systems, Inc.

## Investors

- Integra Ventures (https://capitalatlas.ai/funds/integra-ventures) — Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C, Series D
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series B, Series C
- Emerging Technology Partners (https://capitalatlas.ai/funds/emerging-technology-partners) — Series B, Series C
- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series B
- Hillman Medical Ventures (https://capitalatlas.ai/funds/hillman-medical-ventures) — Series B, Series C
- Stratos Management Systems, Inc. — Series B
- MedVenture Associates (https://capitalatlas.ai/funds/medventure-associates) — Series C, Series D
- CVF Capital Partners — Series C, Series D